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A B S T R A C T
Background: Blood for transfusion is lifesaving and essential to many elements of modern medical practice. The
global blood supply relies on volunteer blood donors. Apheresis is increasingly used to collect blood and requires
anticoagulant to prevent extracorporeal coagulation. Citrate, the standard apheresis anticoagulant, chelates
ionized calcium with consequent perturbations of serum calcium, parathyroid hormone, vitamin D, and markers
of bone remodeling in donors. Cross-sectional studies of bone mineral density (BMD) among apheresis donors
exhibit conflicting results.
Methods: The longitudinal, randomized, controlled ALTRUYST trial (NCT02655055) was undertaken to de-
termine whether BMD declined following high frequency apheresis blood donation over 1 year. The study was
powered at 80% to detect the primary outcome of a 3% decline in BMD. Subjects new to apheresis agreed to
make ≥20 apheresis donations in a one-year period and were randomized to treatment (high frequency
apheresis) or control (no apheresis). Dual-energy x-ray absorptiometry was performed before and after parti-
cipation. Two-sided t-test and multivariable logistic regression were used to assess outcomes.
Findings: Mean lumbar spine BMD did not change during the study among control donors (−0.002 g/cm2,
95%CI [−0.020, 0.016], p=0.78), or among donors in the apheresis arm (mean change= 0.007 g/cm2, 95%CI
[−0.005, 0.018], p=0.24). Mean total hip BMD did not change for control donors (mean change= 0.002 g/
cm2, 95%CI [−0.006, 0.009], p=0.63) or apheresis donors (−0.004 g/cm2, 95%CI [−0.10, 0.002], p=0.16).
Tests for differences in proportions of donors with change in BMD exceeding the least significant change at the
lumbar spine in either a positive [8 apheresis (31%), 4 control (27%), p=0.78] or negative direction [4
apheresis (15%), 5 control (33%)] were statistically non-significant (p=0.18). Proportional increases [0
apheresis (0%), 1 control (7%), p=0.18] and decreases [3 apheresis (12%), 1 control (14%)] were also not
significantly different at the total hip (p=0.61).
Interpretation: ALTRUYST is the first longitudinal trial to demonstrate that apheresis blood collection guidelines
in the United States adequately protect the skeletal health of male volunteer blood donors.
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Research in context
Evidence before this study
Central to the safety and availability of the global blood
supply is the community of volunteer blood donors. Cross-
sectional studies have reported that intermittent exposure to
citrate through apheresis blood donation is associated with
significant declines in donor bone mineral density (BMD). In
contrast, oral potassium citrate at a much lower dose has been
used to treat low bone density with well-documented efficacy.
The impact of citrate exposure during apheresis, either positive or
negative, is important given that BMD is a significant risk factor
for low trauma fracture. It is ultimately unknown what effect
repeated apheresis has on skeletal health.
Added value of this study
We carried out a prospective, randomized, clinical trial testing
the hypothesis that high frequency apheresis blood donation
causes a decline in BMD. Forty-one donors completed the study
and there was no change in bone mineral density among donors
completing a median of 20 apheresis blood donations in the one
year study period. Bone density did not change among members
of the control group who did not undergo apheresis blood
donation.
Implications of all the available evidence
Despite significant, repeated challenges to mineral home-
ostasis among apheresis blood donors, we conclude that current
collection guidelines adequately protect the skeletal health of
adult male, high frequency apheresis blood donors.
1. Introduction
Apheresis blood collections represent an increasing proportion of
collected and transfused blood products in most parts of the world
(Bialkowski et al., 2016). Apheresis involves the collection of specific
blood components (e.g. platelets, red blood cells, plasma) by centrifu-
ging whole blood in an extracorporeal circuit (Okafor et al., 2010).
Anticoagulant is required to prevent coagulation in the circuit and is
mixed with whole blood as it leaves the site of venipuncture. Citrate,
the standard anticoagulant used during apheresis donation procedures
(Hester et al., 1983; Lee and Arepally, 2012), exerts its anticoagulant
effect by chelating ionized calcium (iCa) in donor plasma. Citrate is
returned to apheresis donors intravenously as a mixture with blood
components that have not been harvested. This return occurs every few
minutes and elicits significant declines in ionized calcium (Hester et al.,
1983; Bolan et al., 2001; Szymanski, 1978; Bolan and Leitman, 2002;
Das et al., 2005). Apheresis donors subsequently experience alterations
in circulating concentrations of parathyroid hormone (Bolan et al.,
2001; Silberstein et al., 1986; Toffaletti et al., 1985; Mercan et al.,
1997; Amrein et al., 2010; Bolan et al., 2003) vitamin D (Hiemstra
et al., 2014), and markers of bone remodeling (Amrein et al., 2010;
Bolan et al., 2003; Chen et al., 2009).
Evaluation of BMD among apheresis blood donors has yielded
conflicting results. The prevalence of low BMD, defined as Z- and T-
scores and adjusted for body mass index, average physical activity, and
daily calcium intake, was higher for a group of apheresis donors
(n=102) as compared to a matched control group (Amrein et al.,
2010). Another matched study of 20 apheresis and 20 whole blood
donors, aged 55–70 and female, showed no difference in total hip or
lumbar spine BMD (Boot et al., 2015). Both of these studies were cross-
sectional and hence, purely correlative. Recent findings from a long-
itudinal Swedish study indicate that plasma apheresis does not increase
the risk of fracture in blood donors (Grau et al., 2017); however, these
findings apply to relatively low dose citrate AC exposure and relatively
infrequent plasma apheresis donation.
The collection of platelets by apheresis is increasing in most parts of
the world and confers citrate burden to the donor that is> 85% greater
than for plasma apheresis (Evers and Taborski, 2016). Resolving the
potential impact of the highest apheresis donation frequency, paired
with the associated upper limit of citrate AC burden, represents a cri-
tical knowledge gap in ensuring adequate protections are in place to
preserve the health of volunteer blood donors as it is their altruism that
ensures the availability of life-saving blood products to patients in need.
2. Methods
2.1. Trial design
ALTRUYST (NCT02655055) was a randomized, longitudinal, con-
trolled, single-center clinical trial designed to determine if repeated
exposure to intravenous citrate through apheresis blood donation re-
duces BMD. Due to the fact that the vast majority of apheresis blood
donors, particularly high frequency apheresis blood donors at the par-
ticipating blood center, are Caucasian males, 18–65 year old males were
selected as the population of interest. The demographic and examination
data sets from NHANES were downloaded in April 2015 and used to
estimate mean (1.055 g/cm2) and standard deviation (0.135 g/cm2) of
total lumbar spine BMD for Caucasian males 18–65 years of age in the
United States. These estimates were used to derive distributions of BMD
using a multivariate, normal variable random sampling simulation
(n= 10,000) with covariance for treatment included and change in
lumbar spine BMD over a one year period exceeding the least sig-
nificant change (LSC) at α=0.05 as the primary outcome. The LSC at
the lumbar spine was used in final estimates of sample size which in-
dicated that analysis of 20 apheresis and 15 control subjects was needed
to achieve 80% power. Attrition between the two groups was expected
to differ, with higher rates in the apheresis group anticipated.
Therefore, a 2:1 block randomization scheme was employed with an
overall target enrollment size of 45 (28 apheresis, 17 controls). The
study was registered on ClinicalTrials.gov and approved by the Medical
College of Wisconsin Institutional Review Board (IRB) with ceded re-
view provided by the Marquette University IRB.
2.2. Participants
Male volunteer blood donors 18–65 years of age at enrollment were
recruited at BloodCenter of Wisconsin using standard methods. Subjects
with more than five lifetime apheresis blood donations were deliber-
ately excluded to avoid any potential physiologic adaptation to citrate
exposure. Subjects were also excluded if they had a metal prosthesis or
previous fracture that could interfere with BMD measurement. Those
weighing in excess of 300 lbs, with a previous fragility fracture, a pre-
vious lumbar spine fusion, cystic fibrosis, emphysema, celiac disease,
Crohn's disease, current or past (> 1month duration) use of corticos-
teroids or osteoporosis medications were also excluded. All subjects
provided written informed consent prior to any study procedures.
2.3. Outcomes measurement
Dual energy X-ray absorptiometry (DXA) was performed at the
lumbar spine, total hip, and total body using the GE iDXA™ with Encore
version 11.40.004 software, trabecular bone score version 14.2, located
at Marquette University. Two in vivo precision assessments of the in-
dividual technologist performing all BMD scans were performed in
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August 2015 per ISCD guidelines (Densitometry TISfC, 2007). In sum-
mary, 15 participants were scanned thrice, with repositioning in be-
tween scans. Participants in the precision assessment were male, be-
tween 18 and 65 years of age, generally healthy, and otherwise eligible
for the research study. The technologist's LSC was 0.021 g/cm2 at the
lumbar spine and 0.021 g/cm2 at the total hip.
2.4. Randomization and masking
A simple block randomization (block size of six) was used to allocate
subjects to treatment or control groups. Research subjects and the re-
search technologist were not blinded to treatment allocation. Paired
sets of bone density scans were anonymized and blinded to both
treatment status (apheresis or control) and time point (enrollment
versus follow-up) before blinded clinician review (Dr. Joseph Shaker,
Medical College of Wisconsin) using ISCD criteria (Densitometry TISfC,
2007).
2.5. Study procedures
An interviewer collected questionnaire data at enrollment to con-
firm eligibility and document race, ethnicity, family history of osteo-
penia/osteoporosis, family history of fracture, personal history of
fracture, daily calcium intake, activity level, medication use, and other
parameters that could alter baseline BMD (see Protocol, clinicaltrials.
gov). Baseline DXA was performed prior to the first on-study blood
donation. All subjects with a Z-score < −2.0 or> 2.0 at any mea-
surement site were notified by letter and excluded from further parti-
cipation. All participants received $50 for the completing the
enrollment visit.
A peripheral blood sample was collected in a serum separator tube
at the first on-study blood donation and processed within 30min.
Samples were subsequently frozen at −80 °C and tested (comprehen-
sive metabolic panel and testosterone) within one year at ARUP
Laboratories (Salt Lake City, UT). The duration of apheresis donation
and volume of AC infused into the donor during the first of each pro-
cedure type was extracted from InfoVu, the online apheresis data log-
ging software from TerumoBCT, and used to estimate total donation
duration and volume. ALTRUYST investigators verified that component
blood products derived during the study could be labeled as “voluntary
units” (21 CFR 606.121(c)(8)(v)) per the FDA's Center for Biologics
Evaluation and Research Office in February 2016. Hence, all blood
components derived during ALTRUYST were available for transfusion.
Donors randomized to the apheresis arm were asked to make be-
tween 20 and 26 apheresis blood donations during the subsequent one
year period and received $250 for doing so. Apheresis procedures were
performed using the Trima Accel multi-component apheresis system
(Burgstaler, 2006). Donors randomized to the control arm were asked
to make zero or whole-blood-only donations during the subsequent one
year period and received $100 for doing so. Participants were contacted
one year hence (Gourlay et al., 2012) and returned to Marquette Uni-
versity for repeat questionnaire and BMD data acquisition as at en-
rollment. Subjects with a change in bone density that exceeded the
technologist's LSC, or with Z-score < −2.0 or> 2.0 were reviewed by
the medical monitor and notified by letter. Participants received $50 for
completing the follow-up visit.
Fig. 1. Enrollment schematic showing recruitment, enrollment, ineligibility, and losses to follow-up for the ALTRUYST trial. ITT= intention to treat.
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2.6. Statistical analysis
The distributions of continuous and ordinal variables at baseline
were compared using the t-test statistic and Fisher's exact test, respec-
tively. The primary outcome was defined a priori as a decline in lumbar
spine BMD that exceeded the technologist's LSC and secondary out-
comes were change in total hip BMD and change in trabecular bone
score. The intention to treat analysis included all subjects who com-
pleted follow-up. A per protocol analysis was also performed that in-
cluded only those subjects who complied with the criteria of their
randomization. Multivariable logistic regression was performed using
the questionnaire, laboratory, baseline BMD data, and, treatment arm
as predictors of change in bone density exceeding the LSC. Bilirubin,
alkaline phosphatase, and anion gap were log transformed to achieve
normal distributions. Automated stepwise backwards elimination was
subsequently performed to identify significant predictors of both posi-
tive and negative response. All programming was developed and exe-
cuted in R: a language and environment for statistical computing (Team
RC, 2015). WB had full access to all study data and accepts final re-
sponsibility for the decision to submit for publication.
2.7. Role of the funding source
This work was supported by Marquette University and the
BloodCenter Research Foundation. Neither entity had a role in study
design; the collection, analysis, or interpretation of data; in the writing
of the report; or in the decision to submit the paper for publication.
3. Results
3.1. Enrollment
Among 120 volunteer blood donors assessed for eligibility, 58 en-
rolled in the study (Fig. 1). Seven enrollees were subsequently excluded
for having a bone density Z-score < −2.0 or> 2.0 at enrollment.
Three additional subjects were excluded for having previously under-
gone apheresis more than five times and one subject was excluded for
weighing> 300 lbs. Ultimately, 32 subjects were randomized to the
apheresis arm and 15 to the control arm.
Mean age at enrollment was 43.8 years (SD=13.5) with one donor
(2%) reporting African American race and another (2%) reporting
Hispanic ethnicity (Table 1). Mean height (p=0.89), weight
(p=0.25), and body mass index (BMI) (p=0.38) were no different
between study arms. Baseline laboratory parameters were similar be-
tween groups (p=0.14–0.97), as were the number of previous whole
blood (median= 5, p=0.73) and apheresis (median= 3, p=0.49)
donations. Though lumbar spine bone density was no different between
study arms (p=0.26), bone density at the total hip was, on average,
0.107 g/cm2 higher among those donors randomized to the apheresis
arm (p=0.03) (Table 1).
3.2. Follow-up
ALTRUYST donors made a total of 534 combined blood donations
during the one year study period (Fig. 2). Approximately 20% of sub-
jects from the apheresis arm were not available at follow-up: two
subjects voluntarily withdrew from the study (6%) and four subjects
were lost to follow-up (11%). All 15 (100%) donors randomized to the
control arm complied with the protocol (three made zero whole blood
donations, Fig. 2), whereas five (19%) apheresis donors did not achieve
a minimum of 20 apheresis donations (Fig. 1, “Did not Comply”). The
most common apheresis donation type was a double platelet donation
with mean interval between donations of 17.8 days (Table 2). Donors in
the apheresis arm experienced a median of 20 apheresis blood dona-
tions during the one year study period with the amount of citrate ex-
posure by donation type ranging from 164mL to 657mL (Table 2). The
duration of each donation ranged from just under 30min to more than
two hours in length.
3.3. High frequency apheresis for one year did not alter bone mineral
density
Lumbar spine bone mineral density did not change among donors in
the control arm after one year of participation (1.168 g/cm2 at enroll-
ment, mean change=−0.002 g/cm2, 95%CI [−0.020, 0.016],
p=0.16), nor did it change among donors in the apheresis arm
(1.214 g/cm2 at enrollment, mean change=0.007 g/cm2, 95%CI
[−0.005, 0.018], p=0.24) (Fig. 3). Tests for differences in proportions
of donors with change in BMD exceeding the least significant change
(LSC) at the lumbar spine between the apheresis and control arms in
either a positive [apheresis 8 (31%), control 4 (27%), p=0.78] or
negative direction [apheresis 4 (15%), control 5 (33%)] were statisti-
cally non-significant (p=0.18) (Fig. 4). Performing the per protocol
analysis (i.e. apheresis donors making ≥20 apheresis donations) did
not meaningfully alter these results.
Change in mean BMD at the total hip was not statistically significant
for control donors (1.026 g/cm2 at enrollment, mean
Table 1
Descriptive characteristics of ALTRUYST blood donors at enrollment.
Apheresis No apheresis Total p
n 26 15 41 –
Demographics
Age (mean, SD) 42.6 (13.1) 45.9 (14.3) 43.8
(13.5)
0.46
Caucasian (n, %) 25 (96%) 15 (100%) 44 (98%) –
Latino/Hispanic (n, %) 1 (4%) 0 (0%) 1 (2%) –
Anthropometricsa
Height (in.) 70.4 (2.4) 70.2 (3.2) 70.3 (2.7) 0.89
Weight (lbs) 203.2 (32.2) 191.7 (29.0) 199.0
(31.2)
0.25
Body composition 28.9 (4.7) 27.5 (5.0) 28.4 (4.8) 0.38
Laboratory dataa
Serum sodium (mmol/L) 143 (2.3) 142 (2.1) 143 (2.3) 0.24
Serum potassium (mmol/L) 4.5 (0.3) 4.7 (0.3) 4.6 (0.3) 0.38
Serum chloride (mmol/L) 101 (1.9) 100 (3.0) 101 (2.3) 0.37
Serum carbon dioxide
(mmol/L)
22 (1.5) 21 (1.5) 22 (1.5) 0.19
Anion gap (mmol/L) 20 (2.2) 20 (1.8) 20 (2.0) 0.34
Serum urea nitrogen (mg/dL) 16 (3.7) 15 (5.3) 15 (4.2) 0.80
Serum creatinine (mg/dL) 1.00 (0.14) 0.99 (0.15) 1.00
(0.14)
0.83
Serum glucose (mg/dL) 97 (16) 101 (25) 98 (19) 0.66
Alkaline phosphatase (U/L) 67 (15) 75 (22) 70 (18) 0.33
Aspartate aminotransferase
(U/L)
26 (8) 27 (4) 26 (7) 0.53
Alanine aminotransferase (U/
L)
25 (12) 25 (7) 25 (10) 0.97
Serum calcium (mg/dL) 9.7 (0.4) 9.7 (0.5) 9.7 (0.4) 0.93
Serum inorganic phosphorous
(mg/dL)
3.3 (0.5) 3.5 (0.4) 3.4 (0.5) 0.14
Serum total protein (g/dL) 7.2 (0.4) 7.4 (0.5) 7.3 (0.5) 0.39
Serum albumin (g/dL) 4.6 (0.3) 4.7 (0.3) 4.6 (0.3) 0.49
Serum total bilirubin (mg/dL) 0.6 (0.4) 0.6 (0.3) 0.6 (0.3) 0.95
Adult male testosterone (ng/
dL)
520 (198) 515 (202) 518 (196) 0.94
Previous blood donationsb
Whole blood (n) 6 4 5 0.73
Apheresis (n) 3 3 3 0.49
Bone densitya
Lumbar spine (g/cm2) 1.214 (0.130) 1.168 (0.120) 1.197
(0.127)
0.26
Total hip (g/cm2) 1.133 (0.149) 1.026 (0.140) 1.094
(0.153)
0.03
a Mean (SD).
b Median.
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change= 0.002 g/cm2, CI [−0.006, 0.009], p=0.63) or apheresis
donors (1.133 g/cm2 at enrollment, 1.129 g/cm2 at follow-up, mean
change=−0.004 g/cm2, CI [−0.10, 0.002], p=0.16) (Fig. 3). Pro-
portional increases [apheresis 0 (0%), control 1 (7%), p=0.18] and
decreases [apheresis 3 (12%), control 1 (14%)] were also not sig-
nificantly different (p=0.61) at the total hip (Fig. 4). Performing the
per protocol analysis did not meaningfully alter these results. Multi-
variable logistic regression with change exceeding the LSC in both
positive (gain in BMD) and negative (loss of BMD) directions using
automated stepwise backwards elimination did not identify baseline
covariates that were significantly associated with either outcome
(Table 3).
Mean trabecular bone score was 1.388 (SD=0.098) in the control
group at enrollment and did not significantly change over the one year
study period (1.406 (SD=0.112) at follow-up, mean
change=−0.003, 95%CI [−0.024–0.019], p=0.79). Donors in the
apheresis arm had a mean trabecular bone score at enrollment of 1.474
(SD=0.105) and it did not change over the one year study period
(1.475 (SD=0.133) at follow-up, mean change=0.001, 95%CI
[−0.022, 0.024], p=0.92).
Fig. 2. Cleveland dot plot of donations (solid dots, n=543) and deferrals (open dots, n= 38) from donors during the ALTRUYST study. The top panel shows donors
randomized to apheresis and the bottom panel shows donors randomized to no apheresis (i.e. whole blood only). Each donor is represented as a row with the number
of successful donations made during the study shown to the left.
Table 2
Apheresis collection and anticoagulant exposure characteristics for donors randomized to the treatment arm (high frequency apheresis) during the ALTRUYST trial.
Single Double Triple
Collection information Number of platelet apheresis donations 110 320 62
Concurrent PLASMA COLLECTION n (%) 0 (0%) 4 (1%) 0 (0%)
Mean (SD) collection time (min) 57.6 (21.8) 89.4 (23.3) 97.1 (24.9)
Mean (SD) inter-donation interval (days) 17.8 (14.7)
Anticoagulant exposure Type of Anticoagulant ACD-Aa
Mean (SD) volume (mL) AC infused per procedure 299 (104) 469 (111) 498 (117)
a ACD-A= anticoagulant citrate dextrose solution, solution A (2.13% free citrate ion).
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4. Discussion
ALTRUYST was a prospective, longitudinal, randomized controlled
trial evaluating the role of high frequency platelet apheresis blood
donation on change in BMD and found no significant alterations to BMD
at the lumbar spine, total hip, or significant change in trabecular bone
score. Using individual blood donors as their own controls and per-
forming longitudinal assessment of BMD represent differences from
previous research studies that also tested the hypothesis that apheresis
blood donation impacts bone density. Donors in the ALTRUYST trial
almost exclusively donated platelets by apheresis (< 1% of donations
involved concurrent plasma collections) and received an average of
between 300mL (single platelet apheresis) and 500mL (triple collec-
tions) of AC per procedure with an average of 17 days between ex-
posures. Though we are not able to directly compute dose in milli-
equivalents due to differences in apheresis machine settings, exposure
in this study represents the upper limit of citrate AC exposure to vo-
lunteer platelet apheresis donor in the United States. We conclude that
frequent platelet apheresis, and the associated exposure to citrate AC,
does not induce changes in BMD exceeding 3% in a one year period.
Furthermore, BMD of a control group randomly assigned to no apher-
esis remained unchanged during the study period, consistent with large
studies of the male US population 18–65 years of age (Looker et al.,
2010).
Previous studies demonstrated a higher prevalence of low BMD
among apheresis donors when compared to non-blood donors (Amrein
et al., 2010) or whole blood donor controls (Dettke et al., 2003), in-
dependent of donor gender or age. One study reported no difference
among apheresis and whole blood donors (Boot et al., 2015). These
conflicting results likely stem from the cross-sectional designs employed
in these previous investigations. Analysis of> 140,000 Swedish blood
donors over a 23 year period demonstrated no association between the
risk of fracture and, mostly (94–98%), plasma apheresis (Grau et al.,
2017). Plasma apheresis collections expose donors to a fraction of the
AC that platelet apheresis donors receive (Evers and Taborski, 2016)
and high frequency platelet apheresis donors were not present in the
SCANDAT2 analysis and thus, the potential implications of high fre-
quency platelet apheresis on bone density and fracture risk were not
assessed.
Most ALTRUYST donors in the apheresis arm (21/26, 81%)
achieved 20 or more apheresis donations during the one year study
period and though no fractures occurred during ALTRUYST, trabecular
bone score (TBS) was measured. TBS is an analytic tool that quantifies
the extent of between-pixel differences in x-ray attenuation from DXA
images approximating microarchitectural features of bone that are as-
sociated with increasing bone fragility and susceptibility to fracture
(Jehle et al., 2013; Krueger et al., 2014). TBS did not change among
ALTRUYST donors in the apheresis arm, or among donors in the control
Fig. 3. Boxplots showing change in bone mineral density at the lumbar spine (left) and total hip (right) for control and apheresis donors in the ALTRUYST trial.
Diamonds indicate mean values; median change is represented as the central horizontal bar within the interquartile range box.
Fig. 4. Histograms showing mean change in lumbar spine BMD (top) and total
hip BMD (bottom) in the per protocol analysis with control subjects (light blue)
and apheresis donors (dark blue). p values represent test for proportions, both
decrease and increase exceeding the least significant change, control versus
treatment at the lumbar spine (LS) and total hip (TH). (For interpretation of the
references to color in this figure legend, the reader is referred to the web ver-
sion of this article.)
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arm. This finding is consistent with previous research showing that the
magnitude of change in TBS is less than that of BMD area in the spine
(Krieg et al., 2013; Popp et al., 2013; Senn et al., 2014). The finding
that the upper limit of citrate AC exposure, both in terms of dose and
frequency, failed to produce significant alterations to TBS among do-
nors indicates that current apheresis collection guidelines do not likely
alter fracture risk.
Several potential forms of bias and confounding were addressed in
the design of ALTRUYST. Though mean BMD was higher in the ALT-
RUYST cohort relative to a gender- and age-matched sample of the US
population, this is expected due to a well-known “healthy donor effect”
where volunteer blood donors consistently present with health indices
superior to population norms (Atsma and de Vegt, 2011). Furthermore,
variability in the measure of central tendency among ALTRUYST donors
indicates that individuals within the cohort were not contributing any
outlier effects that could bias our assessment of the study's outcomes.
This is, in part, due to the fact that ALTRUYST deliberately excluded
individuals with BMD that fell outside of a 95% population-based es-
timate of mean BMD (i.e.± 2 standard deviations of Z-score). Predis-
position to diseases of bone and mineral metabolism were solicited
from participants at enrollment, coded as an ordinal variable and as-
sessed using multivariable logistic regression without achieving statis-
tical significance for changes either in the positive or negative direc-
tion. The randomized design of this study ensured that the likelihood of
being assigned to either group was equivalent. Nevertheless, con-
founding could occur if subjects experienced changes to other im-
portant determinants of BMD including physical activity, diet, and
medication use. In addition to excluding subjects with known diseases
of bone and mineral metabolism, subjects were deliberately excluded if
they were taking medications known to impact BMD. Upon follow-up
assessment, no changes in medication use were noted meaning that any
confounding from medication use was absent. Physical activity did not
differ between the two randomized groups, and, changes in physical
activity sufficient to invoke changes in BMD over the one year interval
did not occur. The self-report questionnaire was administered by the
investigative team to avoid any non-response bias. These design fea-
tures and observations indicate that the findings of ALTRUYST are ex-
tremely unlikely to have known bias or confounding that could have
impacted the results of the study and though the potential for residual,
unmeasured confounding can never be completely eliminated, the
complete lack of any significant change in any outcome measured
suggests that any such effect was minimal if present.
ALTRUYST deliberately studied male blood donors because they
constitute the vast majority (approximately 80%) of the apheresis blood
donor population at BloodCenter of Wisconsin, with 85% of higher
frequency donors (defined as ≥15 apheresis donations within a one
year period) also being male. Furthermore, the study recruited donors
with no more than five lifetime apheresis donations so as to avoid any
potential biological adaptation that may occur with repeated exposure
to citrate AC. Though we report no change in bone mineral density
among men, aged 18–65 years, experiencing high frequency apheresis
over a one year period, we are unable to extrapolate these findings to
women of any age. There remains the possibility that high frequency
apheresis affects women differently than men, particularly during the
peri-menopausal period when changes in serum estrogen have been
correlated with large declines in BMD, with supplemental estrogen
improving bone-related health outcomes (Kiel et al., 1987; Weiss et al.,
1980). The scarcity of higher frequency female apheresis donors at the
Table 3
Results of exploratory multivariable logistic regression analysis with change in bone mineral density as the outcome [coefficient (p value)].
Negative change Positive change
Lumbar spine Total hip Lumbar spine Total hip
Apheresis versus no apheresis 0.31 (0.08) 0.56 (0.74) 0.00 (0.99) 0.56 (0.74)
Age −0.02 (0.07) 0.00 (0.94) 0.01 (0.45) 0.00 (0.94)
Risk factors= 1 −0.28 (0.11) 0.11 (0.92) 0.15 (0.54) 0.11 (0.92)
Risk factors= 2 −0.45 (0.07) 0.72 (0.76) 0.11 (0.67) 0.72 (0.76)
Risk factors= 3 −0.40 (0.14) 0.98 (0.71) −0.46 (0.41) 0.98 (0.71)
Risk factors= 4 −3.62 (0.02) 0.74 (0.88) 2.51 (0.12) 0.74 (0.88)
Family risk factors= 1 0.15 (0.29) −0.15 (0.94) −0.11 (0.75) −0.15 (0.94)
Family risk factors= 2 −0.13 (0.27) −0.19 (0.91) 0.31 (0.41) −0.19 (0.91)
Family risk factors= 3 −1.80 (0.04) −0.46 (0.91) 0.76 (0.35) −0.46 (0.91)
Health conditions=1 0.71 (0.05) 0.59 (0.75) −0.27 (0.44) 0.59 (0.75)
Health conditions=2 2.60 (0.05) 0.75 (0.91) −1.06 (0.41) 0.75 (0.91)
Medication use= 1 −1.13 (0.04) −0.24 (0.90) −0.96 (0.17) −0.24 (0.90)
Diet= 3 0.21 (0.16) 0.65 (0.73) −0.05 (0.22) 0.65 (0.73)
Diet= 4 0.30 (0.14) 0.61 (0.79) −0.36 (0.39) 0.61 (0.79)
Diet= 5 0.91 (0.04) −0.19 (0.90) −1.56 (0.09) −0.19 (0.90)
Diet= 6 1.52 (0.02) 0.55 (0.77) −1.70 (0.10) 0.55 (0.77)
Diet= 7 4.18 (0.02) 1.33 (0.75) −1.33 (0.26) 1.33 (0.75)
Body mass index 0.05 (0.05) 0.00 (0.98) 0.06 (0.17) 0.00 (0.98)
Baseline BMD 5.13 (0.02) −1.59 (0.83) −4.86 (0.10) −1.59 (0.83)
Serum sodium 0.09 (0.14) −0.27 (0.73) −0.24 (0.18) −0.27 (0.73)
Serum potassium 0.47 (0.10) −0.73 (0.75) −1.94 (0.09) −0.73 (0.75)
Serum chloride −0.18 (0.08) 0.14 (0.86) 0.11 (0.42) 0.14 (0.86)
Serum carbon dioxide −0.28 (0.03) 0.17 (0.74) 0.21 (0.16) 0.17 (0.74)
Serum urea nitrogen 0.09 (0.03) 0.04 (0.77) −0.10 (0.11) 0.04 (0.77)
Serum creatinine −2.80 (0.04) 2.05 (0.83) 3.97 (0.11) 2.05 (0.83)
Serum glucose −0.02 (0.04) −0.01 (0.82) −0.02 (0.17) −0.01 (0.82)
Alkaline phosphatase −0.01 (0.10) 0.01 (0.87) 0.00 (0.86) 0.01 (0.87)
Aspartate aminotransferase 0.00 (0.52) 0.04 (0.77) 0.00 (0.69) 0.04 (0.77)
Alanine aminotransferase −0.08 (0.03) 0.01 (0.94) 0.07 (0.11) 0.01 (0.94)
Serum calcium −0.93 (0.05) 0.13 (0.97) 1.28 (0.14) 0.13 (0.97)
Serum inorganic phosphorous −0.36 (0.06) 0.12 (0.93) −0.23 (0.33) 0.12 (0.93)
Serum total protein 1.21 (0.06) 0.12 (0.96) −1.23 (0.20) 0.12 (0.96)
Serum albumin −0.83 (0.11) −0.19 (0.96) 2.25 (0.15) −0.19 (0.96)
Serum total bilirubin −0.30 (0.11) 0.19 (0.94) −1.74 (0.07) 0.19 (0.94)
Adult male testosterone 0.00 (0.05) 0.00 (0.64) 0.00 (0.30) 0.00 (0.64)
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blood center studied indicates that any exploration of the impact of
high frequency apheresis on BMD among women would require a multi-
center design Furthermore, the high prevalence of low BMD among
women, especially that increases over the life course (Looker et al.,
1995), indicates this would be an ideal group to evaluate the possible
benefit of repeated alterations to PTH through apheresis (Bialkowski
et al., 2016; Steddon and Cunningham, 2005) that resemble those of
synthetic PTH treatments for osteopenia/osteoporosis with demon-
strable improvement in BMD (Jehle et al., 2013).
Any change in BMD that exceeds the LSC is a clinically meaningful
finding. Thus, another area for potential future investigation is the
observation in ALTRUYST that high frequency apheresis induced
clinically meaningful positive change in some donors and clinically
meaningful negative change in others, particularly at the lumbar spine.
The lumbar spine was deliberately selected as the site of the primary
outcome measure because of the high surface area to volume ratio that
could theoretically experience changes more quickly than other sites.
Though ALTRUYST was not powered to detect such differences, this
observation invokes the possibility that there may be individual dif-
ferences in response to high frequency apheresis. Further research
would be necessary to address this possibility.
5. Conclusions
Despite significant, repeated challenges to mineral homeostasis
among apheresis blood donors through exposure to citrate AC, we
conclude that current collection guidelines adequately protect the
skeletal health of adult male, high frequency apheresis blood donors.
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